Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. - Wikidata - awgldk - TriplyDB

Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.

Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.

http://www.wikidata.org/entity/Q34442318

about

Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells Diabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progression.Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems.Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.7-difluoromethoxyl-5,4'-di-n-octyl genistein inhibits ovarian cancer stem cell characteristics through the downregulation of FOXM1.Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer.Assessment of ovarian cancer spheroid attachment and invasion of mesothelial cells in real time.ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature MicroRNA-10b regulates epithelial-mesenchymal transition by modulating KLF4/Notch1/E-cadherin in cisplatin-resistant nasopharyngeal carcinoma cells.Eradication of Human Ovarian Cancer Cells by Transgenic Expression of Recombinant DNASE1, DNASE1L3, DNASE2, and DFFB Controlled by EGFR Promoter: Novel Strategy for Targeted Therapy of Cancer.In vitro enrichment of ovarian cancer tumor-initiating cells Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.Effective recovery of highly purified CD326(+) tumor cells from lavage fluid of patients treated with a novel cell-free and concentrated ascites reinfusion therapy (KM-CART).Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary.A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype Breaking through an epigenetic wall: re-activation of Oct4 by KRAB-containing designer zinc finger transcription factors.Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome.Onionin A inhibits ovarian cancer progression by suppressing cancer cell proliferation and the protumour function of macrophages Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells.Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer Metastasis of ovarian cancer is mediated by kallikrein related peptidases.Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.Ovarian cancer stem cells: still an elusive entity?Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.Investigating molecular profiles of ovarian cancer: an update on cancer stem cells.Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells.Recently identified drug resistance biomarkers in ovarian cancer.OCT4 controls mitotic stability and inactivates the RB tumor suppressor pathway to enhance ovarian cancer aggressiveness.

P2860

Q26746203-B6DB5C6F-67CE-4A76-BD20-A6F2AC8B60A0 Q28543359-C43ABF80-9ABE-45BB-920C-A315B7727280 Q33591379-F0678E23-5E4D-402E-9C31-9ACC4397C490 Q33628532-59FD71DB-6633-4D9F-A94C-1845D958C588 Q33641924-5EE98D75-9D33-4A01-B39E-C02F970305D5 Q33751321-831FBD77-D434-4765-BCB4-D36D8C8E3ADF Q33754724-469DEB26-81FA-4D97-B67C-A4912285ADEC Q33778490-D4A65A7F-3327-4C28-81CB-62C8F8056403 Q33890763-46158F88-3068-4942-9520-CC959689C1D0 Q34350732-5AE810FE-97C5-43A1-A3E0-1ED58F1F491C Q34483574-583C8803-0E57-4292-833F-827C977E2611 Q34526886-3BB9CBB4-BA47-4238-98F5-5214AFE7BE6F Q35109273-3EC6BEBB-143D-4AB7-8D4E-33995B82F3EE Q35162308-8078DBF4-BDFA-4884-8C56-662633B7A10A Q35780059-50B465EC-FD21-4B7B-8AED-B4625E71F65D Q35936614-C113D4FE-3B31-42E3-B6ED-2A061A8FAB9F Q35961381-F5C7C31F-5E01-47B1-9C07-3B3BAD3905DD Q36180735-F42EE3EA-35CB-4352-92F0-CD394ECCA7A0 Q36232027-63A9664D-70BD-4FDD-A8C8-01D30445EAE0 Q36358324-1266CE48-9985-44B4-8D09-164AECB3EC29 Q36381647-34EC60A8-8A92-4E64-8B27-2D80A0A20590 Q36507476-5AD1DEC3-B8BF-448B-BAD9-5FF26F5E3F2D Q36545528-192D3745-9F24-48E9-9C91-0891C84602CB Q36669986-6BD10859-5FDD-4DD6-A256-919D65DF647A Q36891437-6F06A074-1CA2-4EB7-B3BB-71B731F432AA Q36929682-E80E89D9-71BF-4ED7-9B49-879CE3E0C78C Q37087247-F5704398-1AF1-4C66-A77F-563B3D346B1F Q37137451-3DDCC2CF-8BE1-421E-AC08-1DF862064B12 Q37196532-4452766A-AE89-4589-9F73-E885A3F762B7 Q37276254-10A0D8C3-126A-42AF-BD4A-4D597277F371 Q37459590-45D929FA-3CB0-4994-AA96-248388E50E43 Q37480184-3FA21028-BC0E-4DA1-B608-E81AE1329E2D Q37702541-A24B2481-326F-49EF-BAE6-A8709285EBDD Q37705457-1F084A9A-AD11-43A9-B352-B94658C3C51D Q37713683-8DA1847C-B75F-4FCE-9FF8-9A7ACC4383BC Q37720579-EB26FE39-1962-4BBD-A486-B200D56EA973 Q38203882-83ED0E11-D101-45F9-A621-32045333A9D7 Q38703674-1CDF126D-FF07-4691-AD0E-66538AF76EF5 Q38741073-57DDEF2E-DDC0-4475-AC89-FE4D3B41D43A Q38893887-51EF9D89-4DEE-43BF-97FB-8CCDE0633E02

P2860

Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.

http://www.wikidata.org/entity/Q34442318

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Isolation and characterization ...... chemoresistant ovarian tumors.

@ast

Isolation and characterization ...... chemoresistant ovarian tumors.

@en

Isolation and characterization ...... chemoresistant ovarian tumors.

@nl

type

label

Isolation and characterization ...... chemoresistant ovarian tumors.

@ast

Isolation and characterization ...... chemoresistant ovarian tumors.

@en

Isolation and characterization ...... chemoresistant ovarian tumors.

@nl

prefLabel

Isolation and characterization ...... chemoresistant ovarian tumors.

@ast

Isolation and characterization ...... chemoresistant ovarian tumors.

@en

Isolation and characterization ...... chemoresistant ovarian tumors.

@nl

P1433

Q34442318-53C66A84-3D4B-4C79-AEC0-C01C58A2A648

P1476

Q34442318-04F2B702-30C8-4332-BF55-9AA091B79301

P2093

Q34442318-1C5BE389-5815-4CC4-8109-6416E6AAD97C

Q34442318-2690B8BA-7F9C-4ADE-8232-F5B1DFF55BEE

Q34442318-35BB5B2D-3A98-4030-AF6D-284C04FB6548

Q34442318-8A7A7BE7-541D-4F28-9903-FA0C69ABA497

Q34442318-D4D2B20B-10E0-4C94-9CBC-A6E8BBED39E9

Q34442318-D9100013-2816-4894-8BA6-3EE7A18161FF

Q34442318-E120D3FF-5776-4AF9-BAF6-E7DAD3410A3D

Q34442318-F13D81D9-87A4-42CB-8D26-F5C838D07CF0

Q34442318-F884C9AF-C3B3-4E08-A05E-427886AAF40D

P2860

Q34442318-0402C3D5-1192-4E67-8A51-61FA4F63AAFE

Q34442318-04ABCCBB-4CA6-4E43-BBE8-597F92A8EF7E

Q34442318-05692932-FA3E-47BA-8BA4-32F1803C31FD

Q34442318-08934F51-4763-4380-AED9-8C26451587D4

Q34442318-0ADB6416-ED0F-46C8-AFA0-557FD6DFE236

Q34442318-178DC822-125E-4EA8-BF69-CD80B4F49E1B

Q34442318-196EEC93-C82B-4CFD-98BE-FD57D7504F6A

Q34442318-28E200E4-50DC-466E-B190-166238E74ED5

Q34442318-2B3682A9-1B72-4EED-91D2-3AAAB04AE4A6

Q34442318-2EDEF2CC-4A25-47F0-9848-6A0968FA5FC1

P304

Q34442318-25F87B96-D84C-48C4-BF9A-EBFDCDC19821

P31

Q34442318-A187F8AF-50B8-466F-9420-B3522EF437ED

P356

Q34442318-352ADF57-F36F-4D5A-8961-F0AFC28D70A4

P407

Q34442318-A321E4DF-16F3-46FF-8832-5AD115F65C53

P433

Q34442318-63F5BCCF-5914-470D-9792-E40651B30BC6

P478

Q34442318-06EEBB19-6093-49FB-A4F5-67B25BB976D2

P50

Q34442318-7E9CB958-7EDA-4557-AEB7-DD28E8138F81

Q34442318-9103A143-7F79-4E95-B152-56FFB92C1F84

P577

Q34442318-C3148F5D-A46F-4952-A8B8-37FBFE6A15D7

P5875

Q34442318-2B6042EC-FAA4-4CAE-A33C-6F1DB6A6A787

P698

Q34442318-3932139C-8F80-4C57-9481-AA467DE57613

P921

Q34442318-676AB0A6-2337-4D83-9817-164A64AF5CBF

Q34442318-EB40F405-AC75-4F28-AD76-8733524040DE

P932

Q34442318-38D58C1E-7A43-4027-A04D-3FC9688B7A4A

P356

JOURNAL.PONE.0046858

P1433

P1476

Isolation and characterization ...... chemoresistant ovarian tumors.

@en

P2093

Ardian Latifi

http://www.w3.org/2001/XMLSchema#string

Hongjian Zhu

http://www.w3.org/2001/XMLSchema#string

Jan Pyman

http://www.w3.org/2001/XMLSchema#string

Jock K Findlay

http://www.w3.org/2001/XMLSchema#string

Kaye Stenvers

http://www.w3.org/2001/XMLSchema#string

Maree Bilandzic

http://www.w3.org/2001/XMLSchema#string

Nuzhat Ahmed

http://www.w3.org/2001/XMLSchema#string

Rodney B Luwor

http://www.w3.org/2001/XMLSchema#string

Simon Nazaretian

http://www.w3.org/2001/XMLSchema#string

P2860

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

The epithelial-mesenchymal transition generates cells with properties of stem cells

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

Cancer statistics, 2009

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis

Generation of breast cancer stem cells through epithelial-mesenchymal transition

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression

Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies

P304

e46858

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0046858

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Erik W. Thompson

Michael A. Quinn

P577

2012-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232233079

http://www.w3.org/2001/XMLSchema#string

P698

23056490

http://www.w3.org/2001/XMLSchema#string

P921

P932

3466197

http://www.w3.org/2001/XMLSchema#string